Two independent cohorts, considered as discovery and validation sets, assessed and correlated the proportion of so called partially exhausted (PD-1high/CTLA-4high) tumor-infiltrating CD8+ T cells with objective response and progression free survival to pembrolizumab and nivolumab in melanoma patients, and observed a striking result. The gene discussed is CD8A; the disease is neoplasm.